The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspectiveSetiawan, D., Luttjeboer, J., Westra, T. A., Wilschut, J. C., Suwantika, A. A., Daemen, T., Atthobari, J., Wilffert, B. & Postma, M. J., 1-Apr-2015, In : Expert review of vaccines. 14, 4, p. 589-604 16 p.
Research output: Contribution to journal › Article › Academic › peer-review
- Pharmacoepidemiology and Pharmacoeconomics
- Microbes in Health and Disease (MHD)
- Targeted Gynaecologic Oncology (TARGON)
- Pharmacotherapy and Pharmaceutical Care
- Methods in Medicines evaluation & Outcomes research (M2O)
- Reproductive Origins of Adult Health and Disease (ROAHD)
- Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)
- Value, Affordability and Sustainability (VALUE)
Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations.
|Number of pages||16|
|Journal||Expert review of vaccines|
|Publication status||Published - 1-Apr-2015|
- cervical cancer, cervical cancer screening, cost-effectiveness, HPV vaccination, The Netherlands, HUMAN-PAPILLOMAVIRUS VACCINATION, HPV-16/18 AS04-ADJUVANTED VACCINE, PREVENT CERVICAL-CANCER, BLIND PATRICIA TRIAL, OF-STUDY ANALYSIS, ECONOMIC-EVALUATION, QUADRIVALENT VACCINE, HPV16/18 VACCINATION, CLINICAL BENEFIT, CROSS-PROTECTION